Telehealth in oncology: a cost analysis to evaluate the financial impact of implementing regional trial hubs within a phase 3 cancer clinical trial

被引：3
|
作者：
Alexander, Marliese [1 ,4 ,14 ]
Collins, Ian [6 ,7 ]
Abraham, Patrick [5 ]
Underhill, Craig [12 ,13 ]
Harris, Sam [8 ]
Torres, Javier [9 ,10 ]
Sharma, Sharad [11 ]
Solomon, Benjamin [2 ,4 ]
Tran-Duy, An [5 ]
Burbury, Kate [3 ,4 ]
机构：
[1] Peter MacCallum Canc Ctr, Dept Pharm Dept, Melbourne, Australia
[2] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Australia
[3] Peter MacCallum Canc Ctr, Dept Haematol, Melbourne, Australia
[4] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Australia
[5] Univ Melbourne, Ctr Hlth Policy, Melbourne Sch Populat & Global Hlth, Melbourne, Australia
[6] Victorian Comprehens Canc Ctr, Melbourne, Australia
[7] Deakin Univ, Melbourne, Australia
[8] Bendigo Hlth, Bendigo Canc Ctr, Bendigo, Australia
[9] Goulburn Valley Hlth, Peter Copulos Canc & Wellness Ctr, Shepparton, Australia
[10] Univ Melbourne, Shepparton Clin Sch, Shepparton, Australia
[11] Grampians Hlth, Ballarat Reg Integrated Canc Ctr, Ballarat, Vic, Australia
[12] Albury Wodonga Reg Canc Ctr, Border Med Oncol & Haematol Res Unit, Albury Wodonga, Australia
[13] Univ New South Wales, Rural Med Sch, Sydney, NSW, Australia
[14] Peter MacCallum Canc Ctr, Locked Bag 1ABeckett St, Melbourne, Vic 8006, Australia
来源：
INTERNAL MEDICINE JOURNAL | 2023年 / 53卷 / 12期
基金：
英国医学研究理事会;
关键词：
cost analysis; teletrial; patient cost; cancer; clinical trial;
D O I：
10.1111/imj.16292
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This cost analysis, from a societal perspective, compared the cost difference of a networked teletrial model (NTTM) with four regional hubs versus conventional trial operation at a single metropolitan specialist centre. The Australian phase 3 cancer interventional randomised controlled trial included 152 of 328 regional participants (patient enrolment 2018-2021; 6-month primary end point). The NTTM significantly reduced (AU$2155 per patient) patient travel cost and time and lost productivity.
引用
收藏
页码：2346 / 2349
页数：4
相关论文
共 50 条
  • [11] TELEHEALTH AS A NURSING STRATEGY FOR MONITORING PATIENTS IN AN AMBULATORY ONCOLOGY PHASE 1 CLINICAL TRIAL UNIT: A PILOT STUDY
    Melonas, Deborah
    DelRosso, Alexandria
    Horigan, Nicole
    Capodilupo, Anthony
    Capasso, Virginia
    Lundquist, Debra
    ONCOLOGY NURSING FORUM, 2023, 50 (02)
  • [12] Financial Burden of Cancer Clinical Trial Participation and the Impact of a Cancer Care Equity Program
    Nipp, Ryan D.
    Lee, Hang
    Powell, Elizabeth
    Birrer, Nicole E.
    Poles, Emily
    Finkelstein, Daniel
    Winkfield, Karen
    Percac-Lima, Sanja
    Chabner, Bruce
    Moy, Beverly
    ONCOLOGIST, 2016, 21 (04): : 467 - 474
  • [13] Transparency in reporting of phase 3 cancer clinical trial results
    Patel, Roshal R.
    Verma, Vivek
    Fuller, Clifton D.
    McCaw, Zachary R.
    Ludmir, Ethan B.
    ACTA ONCOLOGICA, 2021, 60 (02) : 191 - 194
  • [14] A QUALITATIVE INTERVIEW STUDY TO EVALUATE SINGLETABLET COMBINATION THERAPY (STCT) WITHIN A PHASE 3 PULMONARY ARTERIAL HYPERTENSION (PAH) CLINICAL TRIAL - INTERIM ANALYSIS
    Davis, S.
    Randall, J.
    Linder, J.
    Rafalski, J.
    Hughes, M.
    Rodriguez, A. A.
    Friberg, M.
    Burbridge, C.
    VALUE IN HEALTH, 2023, 26 (12) : S459 - S460
  • [15] Results of a Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Romosozumab in Men with Osteoporosis
    Lewiecki, E. M.
    Horlait, S.
    Blicharski, T.
    Goemaere, S.
    Lippuner, K.
    Meisner, P.
    Miller, P. D.
    Miyauchi, A.
    Maddox, J.
    Daizadeh, N. S.
    Grauer, A.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [16] An analysis of factors associated with oncology clinical trial activation at University of Illinois Cancer Center Oncology Clinical Trials Office
    Otoo, Mary A.
    Preza, Michelle Uriostigue
    Gavor, Margaret
    Kitterman, Darlene
    Danciu, Oana
    CANCER RESEARCH, 2018, 78 (13)
  • [17] No-cost next generation sequencing of advanced cancer patients within the Strata Precision Oncology Network supports clinical trial enrollment.
    Matrana, Marc Ryan
    Tomlins, Scott A.
    Kwiatkowski, Kat
    Mitchell, Khalis
    Suga, Jennifer Marie
    Dees, Elizabeth Claire
    Burkard, Mark E.
    Khatri, Jamil
    Safa, Malek M.
    Yang, Eddy Shih-Hsin
    Parsons, Benjamin
    Menter, Alex R.
    Thompson, Michael A.
    Gonzalez, Anneliese O.
    Wassenaar, Timothy Robert
    Rhodes, Dan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [18] Race and ethnicity reporting by US federal standards in high-impact phase 2/3 oncology clinical trial publications
    Taparra, Kekoa A.
    Benevente, Ryan
    Shih, Jonathan
    Gimmen, Megan Y.
    Tominez, Paul
    Kekumano, Ka'eo
    Pineda, Eric
    Sherman, Recinda
    Deville, Curtiland
    Peppercorn, Jeffrey M.
    Gomez, Scarlett L.
    Bosserman, Linda D.
    Chino, Fumiko
    Patel, Manali I.
    Shah, Chirag S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [19] Race and Ethnicity Representation in Phase 2/3 Oncology Clinical Trial Publications: A Systematic Review
    Taparra, Kekoa
    Benavente, Ryan
    Shih, Jonathan J.
    Gimmen, Megan Y.
    Tominez, Paul
    Kekumano, Kaeo
    Pineda, Eric
    Halualani, Gisele
    Cakobau, Henrietta
    Ludmir, Ethan B.
    Deville Jr, Curtiland
    Peppercorn, Jeffrey
    Gomez, Scarlett L.
    Bosserman, Linda
    Chino, Fumiko
    Patel, Manali I.
    Shah, Chirag
    JAMA HEALTH FORUM, 2024, 5 (06): : E241388
  • [20] From the Broad Phase II Trial to Precision Oncology: A Perspective on the Origins of Basket and Umbrella Clinical Trial Designs in Cancer Drug Development
    Doroshow, Deborah B.
    Doroshow, James H.
    CANCER JOURNAL, 2019, 25 (04): : 245 - 253
12345